

## CURRICULUM VITAE

### Mohammad Issa Saleh

*Pharmacy Department, Faculty of Pharmacy  
Al-Zaytoonah University of Jordan, Amman, Jordan*

*Phone: +9626-429-1511 (Ext 242) (Office)*

*+9627-983-019-50 (Cell phone)*

*Fax: +962-6-4291432*

*E-mail: m.saleh@zuj.edu.jo*

*Homepage: <https://www.zuj.edu.jo/faculty-of-pharmacy-1/faculty-members/prof/>*



### 1. Personal Data

Date of Birth: December, 9<sup>th</sup> 1981

Nationality: Jordanian

### 2. Education

- Ph. D. (Pharmacokinetics and Pharmacodynamics) 2012, University of Iowa, Iowa city, Iowa, USA
- B.Sc. (Pharmacy) 2004, University of Jordan, Amman, Jordan

### 3. Ph.D. Dissertation

*Population pharmacokinetic/pharmacodynamic analysis of erythropoiesis kinetics,  
University of Iowa, Iowa, Iowa city, USA*

### 4. Employment

#### Academic Positions

- Professor, Department of Biopharmaceutics and Clinical Pharmacy, University of Jordan, Amman, Jordan  
February 07, 2020 – now
- Associate Professor, Department of Biopharmaceutics and Clinical Pharmacy, University of Jordan, Amman, Jordan



QFG11/0110 - 3.1E

Curriculum Vitae Form - Procedures of Appointment and Promotion Committee

February 07, 2016 – February 06, 2020

- Assistant Professor, Department of Biopharmaceutics and Clinical Pharmacy, University of Jordan, Amman, Jordan  
February 07, 2012 – February 06, 2016

### Administrative Positions

- Dean, Faculty, University, City, Country - Period
- Vice Dean, School of Pharmacy, University of Jordan, Amman, Jordan – December, 2019 – September, 2021
- Chairman of Department, School of Pharmacy, University of Jordan, Amman, Jordan – September, 2016- December, 2019
- Assistant Dean, School of Pharmacy, University of Jordan, Amman, Jordan – September, 2014- September, 2016

### 5. Research Interests

- Pharmacokinetics modeling
- Disease progression models
- Pharmacometrics
- Pharmacodynamic modeling

### 6. Membership in Scientific Societies and Associations

- Jordan Pharmaceutical Association
- American Association of Pharmaceutical Scientists

### 7. Teaching Experience

#### • *Graduate Courses*

- Advanced biopharmaceutics and pharmacokinetics
- Clinical Pharmacokinetics
- Clinical research methods and statistics

#### • *Undergraduate Courses*

- Biopharmaceutics
- Pharmacokinetics
- Case studies in pharmacokinetics



QFG11/0110 - 3.1E

Curriculum Vitae Form - Procedures of Appointment and Promotion Committee

- Clinical Pharmacokinetics
- Clinical pharmacokinetics clerkship
- Medical terminology
- Pharmacology 1
- Pharmacology 2

## 8. Supervision of Graduate Research

- Co-Supervisor of MSc. Project of student Hiba Ibrahim Musleh Al Fahmawi titled: "The impact of clinical pharmacist in the identification and management of treatment- related problems in the surgery ward". Passed August, 2020
- Supervisor of MSc. Project of student Dana Helal titled: "Pharmacodynamic modeling of longitudinal change in glycemic response to rosiglitazone therapy in type 2 diabetic patients". Passed July, 2019
- Co-Supervisor of MSc. Project of student Mohannad Hussein Fayeze abu dobay titled: "Pharmacodynamic modeling of Glibenclamide-induced changes in hemoglobin A1C in type2 diabetic patients". Passed May, 2019
- Co-Supervisor of MSc. Project of student Anwar Abdel Qader Hindi Jaffal titled: "Disease progression model to describe longitudinal change in Hemoglobin A1C in response to Gliclazide therapy in type2 Diabetic patients". Passed May, 2019
- Supervisor of MSc. Project of student Mohammad Obaidat titled: "Disease progression model to describe longitudinal change in hemoglobin A1C in response to glimepiride therapy in type 2 diabetic patients". Passed April, 2019
- Co-Supervisor of MSc. Project of student Marwa Ghareeb titled: "A cross-sectional study of cathepsin s and adipolin plasma levels and their correlations with a set of clinical parameters in normoglycemic and hyperglycemic patients with metabolic syndrome in Jordan". Passed December, 2018
- Co-Supervisor of MSc. Project of student Safa'a Ali Al-Qudah titled: "A cross sectional Study of Nesfatin and Lipopolysaccharide Binding Protein Plasma Levels and their Correlations with a set of Clinical Parameters in Normoglycemic and Hyperglycemic Patients with Metabolic Syndrome in Jordan". Passed May 29th, 2018
- Co-Supervisor of MSc. Project of student Govand Yassin Saber titled: "Study of the correlation between plasma levels of irisin and fibroblast growth factor 1 (FGF1) and their correlations with a set of clinical parameter in normoglycemic and hyperglycemic patients with metabolic syndrome in jordan: a cross-sectional study". Passed April 26th, 2018
- Co-Supervisor of MSc. Project of student Sereen Helmi Shoubash titled: "Cardiac adverse events of direct acting antivirals in chronic hepatitis C patients". Passed May 3rd, 2018



QFG11/0110 - 3.1E

Curriculum Vitae Form - Procedures of Appointment and Promotion Committee

- Supervisor of MSc. Project of student Islam Mohammad Al-Ashram titled: "Evaluation of the renal safety of direct acting antivirals in chronic hepatitis C patients". Passed May 3rd, 2018
- Supervisor of MSc. Project of student Suhad Bani Melhem titled: "Patients characteristics associated with virological response in patients with chronic hepatitis C infection receiving peginterferon alfa-2a and ribavirin combination". Passed April 27th, 2017
- Supervisor of MSc. Project of student Nagham Nafiz Hindi titled: "Patient characteristics associated with chronic hepatitis C induced neutropenia". Passed April 17th, 2017
- Supervisor of MSc. Project of student Ghaida Tayseer Nsour titled: "Patient characteristics associated with chronic hepatitis C induced thrombocytopenia". Passed March 15th, 2017

## 9. Membership of Committees

- **National and International**
  - *Clinical Study committee, Jordan Food and Drug Administration*
  - *Bioequivalence committee, Jordan Food and Drug Administration*
  - *Bioequivalence bylaws committee, Jordan Food and Drug Administration*
- **University**
  - *Graduate study committee*

## 10. Professional and Scientific Meetings

### *Scientific Meetings Organized*

Provide bulleted or numbered list with name of conference or symposium or workshop etc., place, and date

### *Participation in Scientific meetings*

Provide bulleted or numbered list with name of conference or symposium or workshop etc., place, and date

## 11. Participation in or organization of curricular and/or extra-curricular activities

- The third international conference of the Faculty of Pharmacy/ The University of Jordan 2012
- Mohammad I Saleh, Modeling longitudinal changes in opiate addiction status after a short-term stabilization with buprenorphine , The 15th Scientific Congress of the Jordanian Pharmacists Association: "Pharmacy Perspectives" An Evolving Role in Community Health, April 3rd-5th, 2014



QFG11/0110 - 3.1E

Curriculum Vitae Form - Procedures of Appointment and Promotion Committee

- Sameh Al-Zubiedi, Mohammad Saleh, Pharmacogenetic-guided warfarin dosing algorithm in African American, Pharmacology 2014 (British Pharmacological Society), 16-18 December, 2014, Queen Elizabeth II Conference Centre, London
- Mohammad I. Saleh, Sameh Alzubiedi, Warfarin dosing algorithm using artificial neural networks, Faculty of Pharmacy Open day, April 29th 2015.
- N Gupta, M Saleh, K Venkatakrishnan, Switch from BSA-based dosing to fixed dosing for the investigational drug ixazomib citrate (IC): application of modeling and simulation to influence posology decisions in oncology drug development, Clinical Pharmacology & Therapeutics (2012)

## 12. Publications

1. Dodin YI, Suyagh MF, **Saleh MI**, Nuseir ZT, Aburuz SM, Al-Qudah AA, Masri AT, Younes AM, Al-Ghazawi MA. **Population Pharmacokinetics Modeling of Lamotrigine in Jordanian Epileptic Patients Using Dried Blood Spot Sampling**. Drug Research. 2021;71(08):429-37.
2. Darwish R, **Saleh M**, Ammar K, AlMasri M. **Impact of International Accreditation in Pharmacy Education: Pharmacy School Students' Perspective**. Indian Journal of Pharmaceutical Education and Research. 2021;55(2s):s364-s72.
3. Al-Ghazawi M, **Saleh MI**, Najib O, Salem I, Najib N. **Population Pharmacokinetics of Ibrutinib in Healthy Adults**. European Journal of Drug Metabolism and Pharmacokinetics. 2021;46(3):405-13.
4. Ashram I, **Saleh M**. **Evaluation of the Renal Safety of Direct Acting Antivirals in Chronic Hepatitis C Patients**. Journal of Advances in Medical and Pharmaceutical Sciences. 2021:34-45.
5. Abdel Jalil MH, Abdullah N, Alsous MM, **Saleh M**, Abu-Hammour K. **A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population**. British Journal of Clinical Pharmacology. 2020;86(7):1267-80.
6. **Saleh M**. **The impact of partial blood replacement on postoperative outcome for pediatric patients with cyanotic heart disease**. Journal of Cardiovascular Medicine and Cardiology. 2020;7(2):167-88.
7. **Saleh M**. **Blood conservation protocol based on modified ultrafiltration towards bloodless pediatric surgery**. Archives of Clinical Hypertension. 2020;6(1):001-12.
8. Kasabri V, Al-Ghareeb MI, **Saleh MI**, Suyagh M, Halaseh L, Al-Sarraf I, AlAlawi S. **Proportional correlates of adipolin and cathepsin S in metabolic syndrome patients with and without prediabetes**. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019;13(4):2403-8.
9. Saber GY, Kasabri V, **Saleh MI**, Suyagh M, Halaseh L, Jaber R, Abu-Hassan H, Alalawi S. **Increased irisin versus reduced fibroblast growth factor1 (FGF1) in relation to adiposity, atherogenicity and hematological indices in metabolic syndrome patients with and without prediabetes**. Hormone molecular biology and clinical investigation. 2019;38(1).



10. Saleh MI, Bani Melhim S. **A time-to-event analysis describing virologic response in patients with chronic hepatitis C infection.** Journal of Chemotherapy. 2019;31(5):274-83.
11. Hindi NN, Saleh MI. **Patient characteristics associated with pegylated interferon alfa-2a induced neutropenia in chronic hepatitis C patients.** Clinical and Experimental Pharmacology and Physiology. 2018;45(7):636-42.
12. Kasabri V, Saleh MI, Suyagh M, AlAlawi S, Yasin N. **Cross-Sectional correlates of nesfatin and lipopolysaccharide binding protein in metabolic syndrome patients with and without prediabetes.** Hormone molecular biology and clinical investigation. 2018;36(3).
13. Saleh M, Bani Melhim S, Al-Ramadhani H, Alzubiedi S. **Bayesian population pharmacokinetic modeling of eltrombopag in chronic hepatitis C patients.** European Journal of Drug Metabolism and Pharmacokinetics. 2018.
14. Saleh M, Hindi N. **A population pharmacodynamic model characterizing neutropenia associated with pegylated interferon alpha 2-a therapy in patients with chronic hepatitis C viral infection.** Naunyn-Schmiedeberg's Archives of Pharmacology. 2018:1-11.
15. Zalloum N, Saleh MI, Al Haj M, Balbisi M, Al-Ghazawi M. **Population pharmacokinetics of vancomycin in Jordanian patients.** Tropical Journal of Pharmaceutical Research. 2018;17(2):351-8.
16. Alshogran OY, Magarbeh LS, Alzoubi KH, Saleh MI, Khabour OF. **Evaluation of the impact of waterpipe tobacco smoke exposure on the activity and expression of rat hepatic CYP450: a pharmacokinetic study.** Inhalation toxicology. 2018;30(13-14):519-26.
17. Alsous M, Hamdan I, Saleh M, McElnay J, Horne R, Masri A. **Predictors of nonadherence in children and adolescents with epilepsy: A multimethod assessment approach.** Epilepsy & Behavior. 2018;85:205-11.
18. Alkhalidi B, AlKhatib HS, Saleh M, Hamed S, Bustanji Y, Al Bujuq N, Najib N, Torrado-Susana S, Sallam A-S. **Clarithromycin Laurate Salt: Physicochemical Properties and Pharmacokinetics after Oral Administration in Humans.** Pharmaceutical Development and Technology. 2018.
19. Alzubiedi S, Saleh MI. **Predictors of severe thrombocytopenia secondary to peginterferon alfa-2a treatment in subjects with hepatitis C virus infection.** American journal of therapeutics. 2017;24(6):e670-e5.
20. Saleh MI. **A Bayesian Approach for Population Pharmacokinetic Modeling of Pegylated Interferon  $\alpha$ -2a in Hepatitis C Patients.** Clinical Pharmacokinetics. 2017:1-11.
21. Alzubiedi S, Saleh MI. **Pharmacogenetic-guided warfarin dosing algorithm in African-Americans.** Journal of cardiovascular pharmacology. 2016;67(1):86-92.
22. Saleh MI. **Clinical Predictors Associated With Warfarin Sensitivity.** American journal of therapeutics. 2016;23(6):e1690-e4.
23. Saleh MI, Obeidat AR, Anter HA, Khanfar AA. **Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection.** Clinical and Experimental Pharmacology and Physiology. 2015;42(10):1030-5.



24. Saleh M. **Modeling longitudinal changes in buprenorphine treatment outcome for opioid dependence.** Pharmacopsychiatry. 2014;47(07):251-8.
25. Saleh M. **Predictors of long term opioid withdrawal outcome after short-term stabilization with buprenorphine.** Eur Rev Med Pharmacol Sci. 2014;18(24):3935-42.
26. Saleh MI, Alzubiedi S. **Dosage individualization of warfarin using artificial neural networks.** Molecular diagnosis & therapy. 2014;18(3):371-9.
27. Saleh MI, Nalbant D, Widness JA, Veng-Pedersen P. **Population pharmacodynamic analysis of erythropoiesis in preterm infants for determining the anemia treatment potential of erythropoietin.** American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2013;304(9):R772-R81.
28. Gupta N, Saleh M, Venkatakrisnan K. **SWITCH FROM BSA-BASED DOSING TO FIXED DOSING FOR THE INVESTIGATIONAL DRUG IXAZOMIB CITRATE (IC): APPLICATION OF MODELING AND SIMULATION TO INFLUENCE POSOLOGY DECISIONS IN ONCOLOGY DRUG DEVELOPMENT.: PII-92.** Clinical Pharmacology & Therapeutics. 2012;91.
29. Mock DM, Matthews NI, Zhu S, Strauss RG, Schmidt RL, Zimmerman MB, Nalbant D, Freise KJ, Saleh M, Veng-Pedersen P. **Comparison of red blood cell survival in sheep determined using red blood cells labeled with either biotin at multiple densities or [14C] cyanate: validation of a model to study human physiology and disease.** Transfusion. 2012;52(5):963-73.
30. Saleh MI, Widness JA, Veng-Pedersen P. **Pharmacodynamic analysis of stress erythropoiesis: change in erythropoietin receptor pool size following double phlebotomies in sheep.** Biopharmaceutics & drug disposition. 2011;32(3):131-9.
31. Nalbant D, Saleh M, Goldman FD, Widness JA, Veng-Pedersen P. **Evidence of receptor-mediated elimination of erythropoietin by analysis of erythropoietin receptor mRNA expression in bone marrow and erythropoietin clearance during anemia.** Journal of Pharmacology and Experimental Therapeutics. 2010;333(2):528-32.
32. Nalbant D, Saleh M, Goldman FD, Widness JA, Veng-Pedersen P. **METABOLISM, TRANSPORT, AND PHARMACOGENOMICS-Evidence of Receptor-Mediated Elimination of Erythropoietin by Analysis of Erythropoietin Receptor mRNA Expression in Bone Marrow and Erythropoietin Clearance During Anemia.** Journal of Pharmacology and Experimental Therapeutics. 2010;333(2):528.